Published in Trends Pharmacol Sci on December 04, 2007
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A (2010) 1.91
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med (2012) 1.85
Killing cells by targeting mitosis. Cell Death Differ (2012) 1.65
Analysis and verification of the HMGB1 signaling pathway. BMC Bioinformatics (2010) 1.20
AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med (2013) 1.19
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer (2010) 1.16
Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene (2011) 1.13
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood (2012) 1.11
Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene (2012) 1.07
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. ACS Med Chem Lett (2010) 1.04
Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells. Mol Cancer Res (2010) 0.99
Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention. Cancer Prev Res (Phila) (2010) 0.99
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99
New combination therapies with cell-cycle agents. Curr Opin Investig Drugs (2008) 0.98
Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci U S A (2012) 0.97
Asthma: beyond corticosteroid treatment. Arch Med Sci (2013) 0.95
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol (2009) 0.94
Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J Exp Clin Cancer Res (2011) 0.93
CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene (2013) 0.93
Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat (2011) 0.91
Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells. Exp Ther Med (2013) 0.90
Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem (2011) 0.90
Knocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin. PLoS One (2009) 0.90
Disrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer. Drug News Perspect (2008) 0.89
Growth kinetics of CD133-positive prostate cancer cells. Prostate (2012) 0.89
CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury. Am J Physiol Renal Physiol (2013) 0.89
Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents. Inorg Chem (2011) 0.89
The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo) (2013) 0.89
Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress. Haematologica (2015) 0.89
Direct interactions with both p27 and Cdk2 regulate Spy1-mediated proliferation in vivo and in vitro. Cell Cycle (2016) 0.88
Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors. Virology (2011) 0.88
A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget (2015) 0.86
Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue. J Med Chem (2009) 0.86
Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development. ISRN Oncol (2013) 0.84
Loss of anchorage in checkpoint-deficient cells increases genomic instability and promotes oncogenic transformation. J Cell Sci (2009) 0.83
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget (2015) 0.83
Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. Cancer Biol Ther (2014) 0.82
Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling. PLoS One (2012) 0.82
Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am (2013) 0.82
Antitumor activity of cell-permeable p18(INK4c) with enhanced membrane and tissue penetration. Mol Ther (2012) 0.81
PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells. Int J Oncol (2010) 0.81
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica (2009) 0.81
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. ACS Med Chem Lett (2012) 0.80
CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. Nat Commun (2015) 0.80
Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. Int J Mol Sci (2015) 0.79
Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication. J Virol (2013) 0.79
A chrysin derivative suppresses skin cancer growth by inhibiting cyclin-dependent kinases. J Biol Chem (2013) 0.78
Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets. ACS Med Chem Lett (2011) 0.78
Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation. Oncotarget (2016) 0.77
Cyclin-dependent kinase 4 signaling acts as a molecular switch between syngenic differentiation and neural transdifferentiation in human mesenchymal stem cells. Cell Cycle (2013) 0.77
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther (2016) 0.76
Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res (2014) 0.76
Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor. Invest New Drugs (2010) 0.76
Identification and structural-functional analysis of cyclin-dependent kinases of the cattle tick Rhipicephalus (Boophilus) microplus. PLoS One (2013) 0.75
New directions for drug-resistant breast cancer: the CDK4/6 inhibitors. Future Med Chem (2015) 0.75
P-TEFb goes viral. Inside Cell (2015) 0.75
Overexpression of miR-26b-5p regulates the cell cycle by targeting CCND2 in GC-2 cells under exposure to extremely low frequency electromagnetic fields. Cell Cycle (2016) 0.75
Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. J Biol Chem (2011) 0.75
Identification of genes associated with laryngeal squamous cell carcinoma samples based on bioinformatic analysis. Mol Med Rep (2015) 0.75
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells. Acta Pharmacol Sin (2016) 0.75
Structural prediction of the interaction of the tumor suppressor p27(KIP1) with cyclin A/CDK2 identifies a novel catalytically relevant determinant. BMC Bioinformatics (2017) 0.75
SZRD1 is a Novel Protein that Functions as a Potential Tumor Suppressor in Cervical Cancer. J Cancer (2017) 0.75
Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor. J Cancer (2017) 0.75
A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer. Sci Rep (2017) 0.75
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
A pericyte origin of spinal cord scar tissue. Science (2011) 4.12
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet (2007) 3.30
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol (2011) 3.10
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Cell cycle kinases in cancer. Curr Opin Genet Dev (2007) 2.46
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem (2001) 2.07
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A (2006) 1.93
Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab (2012) 1.81
What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell (2005) 1.78
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66
Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene (2003) 1.62
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol (2003) 1.52
DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol (2010) 1.49
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology (2013) 1.48
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest (2008) 1.38
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell (2005) 1.23
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol (2009) 1.22
3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors. Bioorg Med Chem Lett (2005) 1.15
Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol (2013) 1.15
Overall Cdk activity modulates the DNA damage response in mammalian cells. J Cell Biol (2009) 1.14
Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A (2013) 1.11
PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood (2011) 1.10
Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J (2012) 1.08
Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell (2006) 1.08
Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res (2006) 1.03
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem (2009) 1.03
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci U S A (2011) 1.02
Mice thrive without Cdk4 and Cdk2. Mol Oncol (2007) 1.02
Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6. J Biol Chem (2011) 1.01
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica (2010) 0.98
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res (2005) 0.96
Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett (2010) 0.93
Driving the cell cycle to cancer. Adv Exp Med Biol (2003) 0.93
NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands. J Med Chem (2002) 0.92
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol (2006) 0.91
Cdk6-dependent regulation of G(1) length controls adult neurogenesis. Stem Cells (2011) 0.88
Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res (2010) 0.88
Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4). Mol Cell Neurosci (2007) 0.87
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. PLoS One (2013) 0.82
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica (2012) 0.82
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem (2010) 0.81
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. Bioorg Med Chem Lett (2012) 0.81
Ion channel blockers for the treatment of neuropathic pain. Future Med Chem (2010) 0.80
Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis. J Chem Inf Model (2005) 0.80
Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics (2013) 0.80
Using cells devoid of RAS proteins as tools for drug discovery. Mol Carcinog (2009) 0.79
Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. J Med Chem (2010) 0.78
Benzodipyrazoles: a new class of potent CDK2 inhibitors. Bioorg Med Chem Lett (2005) 0.78
Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. J Mol Graph Model (2005) 0.78
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor. Bioorg Med Chem Lett (2012) 0.78
Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase. Adv Exp Med Biol (2003) 0.78
Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. J Med Chem (2010) 0.77
An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. Mol Biosyst (2010) 0.77
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. Bioorg Med Chem Lett (2012) 0.77
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases. Invest New Drugs (2012) 0.77
Mouse models of cancer. Mol Oncol (2013) 0.76
Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int J Cancer (2006) 0.76
Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors. Mol Cell Biol (2014) 0.76
HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. Br J Haematol (2010) 0.76
An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes. Curr Med Chem Anticancer Agents (2005) 0.76
Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. PLoS One (2012) 0.75
IP issues facing researchers by Gino D'Oca. Pharm Pat Anal (2012) 0.75
Differentiation between [1,2,4]triazolo[1,5-a] pyrimidine and [1,2,4]triazolo[4,3-a]-pyrimidine regioisomers by 1H-15N HMBC experiments. Magn Reson Chem (2010) 0.75
6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors. ChemMedChem (2007) 0.75
Kinase inhibitors for CNS diseases: an analysis of the recent patent literature. Pharm Pat Anal (2012) 0.75
Mariano Barbacid: director of Spain's first national cancer centre. Interviewed by Adrian Burton. Lancet Oncol (2002) 0.75
A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor. Bioorg Med Chem Lett (2006) 0.75